SCOTT HEPFORD

Scott Hepford is CEO of a biotech company, Well Cell Global LLC, and its affiliate, Well Cell Support LLC, which own and license multiple patents, patents pending, and other intellectual property rights to Physiologic Insulin Resensitization® (PIR®), a method to aid physicians in their treatment of diabetes and other metabolic disorders. (More information, including peer-reviewed medical journal articles, may be found at www.wellcellglobal.com.)

Having been an investor, serial entrepreneur, and operations executive with 20+ years’ experience managing and growing public and private companies, Scott is now focused on helping to make PIR the worldwide standard of care. With a history of 300,000+ safe and efficacious infusion treatments by hundreds of Well Cell licensees, PIR is now undergoing randomized clinical trials to obtain even more objective results and widespread use.

A father of two, Scott lives in Houston with Asher and Alegria, and they are fast becoming world travelers and good will ambassadors.